VitaNova Life Sciences (VNOV) Cash from Discontinued Operations (2017 - 2019)

VitaNova Life Sciences (VNOV) reported Cash from Discontinued Operations of 50.0 for Q2 2019, up 99.7% quarter-over-quarter from 16538.0 in Q4 2017.

VitaNova Life Sciences (VNOV) Cash from Discontinued Operations (2017 - 2019) Analysis & Trends

VitaNova Life Sciences has reported Cash from Discontinued Operations for 2 years, with the latest figure at 50.0 in Q2 2019.

For the quarter ending Q2 2019, Cash from Discontinued Operations changed N/A year-over-year to 50.0; the trailing twelve-month figure through Apr 2020 stood at 50.0 (changed N/A YoY), and the FY2019 full-year result was 57054.0, up 840.96% from the prior year.
Cash from Discontinued Operations for Q2 2019 stood at 50.0, up from 16538.0 in the prior quarter.
The five-year high for Cash from Discontinued Operations was 50.0 in Q2 2019, with the low at 16538.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Discontinued Operations (Qtr)
1	Akso Health	2,315,158.81 Bn	2,315,158.63 Bn	-	-
2	Mckesson	92.76 Bn	89.18 Bn	4.04 Bn	-
3	Cencora	52.82 Bn	50.83 Bn	3.59 Bn	-
4	Cardinal Health	52.17 Bn	48.39 Bn	2.50 Bn	-
5	Henry Schein	9.19 Bn	9.71 Bn	1.07 Bn	-
6	Accendra Health	246.88 Mn	-90.00 Mn	312.39 Mn	-
7	Edap Tms	161.92 Mn	146.92 Mn	8.15 Mn	-
8	111	107.47 Mn	25.61 Mn	23.58 Mn	-
9	Cosmos Health	9.42 Mn	7.26 Mn	1.38 Mn	-
10	VitaNova Life Sciences	-	-	316,343.00	-

Download Data